Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD (TRILOGY)

7. Mai 2026 aktualisiert von: Chiesi Farmaceutici S.p.A.

A Phase 3 Randomised Double Blind Randomised Parallel Multinational Trial Comparing a Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate to Foster® in Patients With Chronic Obstructive Pulmonary Disease

Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to demonstrate the superiority of the triple fixed combination of beclometasone + formoterol + glycopyrrolate (BDP/FF/GB) administered via pressurised metered dose inhaler (pMDI) over the equivalent dose of Foster® (beclometasone dipropionate (BDP) / formoterol fumarate (FF), in patients diagnosed with chronic obstructive pulmonary disease (COPD) after 52 weeks of treatment.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This 52-week randomised 2 parallel groups study evaluated the superiority of fixed triple therapy with Inhaled Corticosteroid (ICS) / Long-Acting β2-Agonist (LABA) / Long-Acting Muscarinic Antagonist (LAMA) compared with ICS/LABA in patients with severe to very severe diagnosed of COPD.

Patients' eligibility was checked during the screening visit including the review of medical history, spirometry assessments, routine labs, physical examination, 12-lead electrocardiogram (ECG), vital signs measurement, prior to entering a 2-week open-label run-in period with BDP/FF to establish a baseline.

After the run-in period, eligible patients were randomised, to either fixed triple therapy BDP/FF/GB or BDP/FF treatment group. During the 52-week treatment period, patients who completed the study did have 5 subsequent visits post randomisation scheduled respectively after 4, 12, 26, 40, and 52 weeks of treatment. During these visits, pre-dose and post-dose spirometry, 12-lead ECG, vital signs, and dyspnoea assessments were performed. Rescue medication use, compliance with the treatment, and EXACT-PRO questionnaire [EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO)] were recorded daily (via an electronic diary) during the run-in and randomised treatment periods.

For pharmacovigilance purposes, adverse events (AE) were recorded from the time of patient informed consent signature until subject's study participation ended (Week 52 or early discontinuation).

Studientyp

Interventionell

Einschreibung (Tatsächlich)

1368

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Ungarn
      • Szeged, Ungarn, 6722
        • Dr Beatrix BALINT

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

40 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Male or female adults aged ≥ 40 years with a diagnosis of COPD
  • Current smokers or ex-smokers
  • A post-bronchodilator Forced Expiratory Volume in the 1st Second (FEV1) < 50% of the predicted normal value and a post- bronchodilator FEV1/ Forced Vital Capacity (FVC) < 0.7
  • At least one exacerbation in the 12 months preceding the screening visit

Exclusion Criteria:

  • Pregnant or lactating women
  • Diagnosis of asthma or history of allergic rhinitis or atopy
  • Patients treated with non-cardioselective β-blockers in the month preceding the screening visit
  • Patients treated for exacerbations in the 4 weeks prior to screening visit
  • Patients treated with long-acting antihistamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study or if taken as PRN
  • Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia
  • Known respiratory disorders other than COPD
  • Patients who have clinically significant cardiovascular condition

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Beclometasone/Formoterol/Glycopyrrolate
CHF 5993 pMDI 100/6/12.5 µg 2 inhalations bid
Arzneimittel: Beclometasone/Formoterol/Glycopyrrolate
Active drug tested
Andere Namen:
  • BDP/FF/GB or CHF 5993 pMDI 100/6/12.5 µg
Aktiver Komparator: Beclometasone/Formoterol
Foster® 100/6 µg 2 inhalations bid
Arzneimittel: Beclometasone/Formoterol
Active comparator
Andere Namen:
  • Foster® or CHF 1535 pMDI 100/6 µg

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
1_Change From Baseline in Pre-dose Morning Forced Expiratory Volume in the 1st Second (FEV1) -- at Week 26
Zeitfenster: Baseline (Week 0), Week 26.

Changes from baseline in pre-dose morning FEV1 to visit at Week 26.

FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
Baseline (Week 0), Week 26.
2_Change From Baseline in 2-hour Post-dose FEV1 -- at Week 26
Zeitfenster: Baseline (Week 0) to 2-hour post-dose at Week 26.

Change from baseline in 2-hour post-dose FEV1, at Week 26.

FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
Baseline (Week 0) to 2-hour post-dose at Week 26.
3_Transition Dyspnoea Index (TDI) Focal Score -- at Week 26
Zeitfenster: Baseline (Week 0), Week 26.

Transition Dyspnoea Index (TDI) focal score is a symptom-based variable tool, used to assess breathlessness and the impact of intervention. BDI/TDI is a clinical rating method based on a validated tool that measures the impact of dyspnoea based on 3 domains: functional impairment, magnitude of task, and magnitude of effort. BDI focal score is the baseline value from which TDI focal score is assessed.

BDI scores range from 0 (very severe impairment) to 4 (no impairment) for each domain with the baseline focal score consisting of the sum of each domain (i.e. from 0 to 12). Change from baseline in dyspnoea severity was measured using the TDI. TDI score ranges from -3 (major deterioration) to +3 (major improvement) for each domain, with the TDI focal score consisting of the sum of each domain (i.e. from -9 to +9). A higher total score indicates improvement, while a lower or negative score indicates worsening symptoms.

BDI=Baseline Dyspnoea Index TDI=Transition Dyspnoea Index
Baseline (Week 0), Week 26.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
4_Change From Baseline in Pre-dose Morning FEV1 -- at All the Other Clinic Visits
Zeitfenster: Baseline (Week 0), Week 4. 12, 40, 52.

Change from baseline in pre-dose morning FEV1, at all the other clinic visits.

Please note: results at visit Week 26, are presented as the primary outcome measure #1 for this study.

FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
Baseline (Week 0), Week 4. 12, 40, 52.
5_Change From Baseline to the Average in Pre-dose Morning FEV1 -- Over the Treatment Period
Zeitfenster: Baseline (Week 0), Week 4, 12, 26, 40, 52.

Changes from baseline for the average in pre-dose morning FEV1 over the treatment period.

FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
Baseline (Week 0), Week 4, 12, 26, 40, 52.
6_Number of Participants Defined as Responders Wrt. to FEV1 -- Change From Baseline in Pre-dose Morning FEV1 ≥100 mL -- at Week 26 and Week 52
Zeitfenster: Baseline (Week 0), Week 26, Week 52.

Number of participants defined as responders wrt. to FEV1 -- at Week 26 and Week 52.

FEV1 response was defined as a change from baseline in pre-dose morning FEV1 of ≥100 mL. If the change from baseline was <100 mL, the patient was classified as a non-responder in terms of FEV1. Subjects with missing pre-dose morning FEV1 value at the pre-specified tested time points were also classified as non-responders.

FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
Baseline (Week 0), Week 26, Week 52.
7_Change From Baseline in 2-hour Post-dose of FEV1 -- at All the Other Clinic Visits
Zeitfenster: Baseline (Week 0), Week 4, 12, 40, 52.

Change from baseline in 2-hour post-dose of FEV1, at all the other clinic visits.

Please note: a) results at visit Week 26, are presented as the primary outcome measure #2 for this study; b) for Week 0, the measurement shown in the results table below was made 2 h after the baseline measurement i.e. pre-treatment at study baseline.

FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
Baseline (Week 0), Week 4, 12, 40, 52.
8_Change From Pre-dose to 2-hour Post-dose FEV1 -- at All Study Visits
Zeitfenster: Week 4, 12, 26, 40, 52.

Change from pre-dose to 2-hour post-dose value of FEV1, at study visits on Week 4, 12, 26, 40, and 52.

FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
Week 4, 12, 26, 40, 52.
9_Transition Dyspnoea Index (TDI) Focal Score -- at All Study Visits
Zeitfenster: Baseline (Week 0), Week 4, 12, 40, 52.

TDI focal score is a symptom-based tool, used to assess breathlessness and the impact of intervention.

BDI/TDI is a clinical rating method based on a validated tool that measures the impact of dyspnoea on 3 domains: functional impairment, magnitude of task, and magnitude of effort.

TDI tool and its scoring system are defined in the outcome measure #3 of this PRS study entry.

Please note: Results at Week 26, are presented as the primary outcome measure #3 for this PRS study entry.

BDI=Baseline Dyspnoea Index TDI=Transition Dyspnoea Index
Baseline (Week 0), Week 4, 12, 40, 52.
10_Number of Participants With Transition Dyspnoea Index (TDI) Response (Focal Score ≥1) -- at Week 26 and Week 52
Zeitfenster: Week 26, Week 52.

Number of participants with transition dyspnoea index (TDI) response (focal score ≥1) -- at Week 26 and Week 52.

TDI tool and its scoring system are defined in the outcome measure #3 of this PRS study entry.

TDI response was defined as a TDI focal score of ≥1. If the TDI focal score was <1, the patient was classified as a non-responder in terms of TDI. Patients with missing TDI focal score at the pre-specified tested time points were also classified as non-responders.
Week 26, Week 52.
11a_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Total Score
Zeitfenster: Baseline (Week 0), Week 4, 12, 26, 40, 52.

Change from baseline in Saint George's respiratory questionnaire (SGRQ) Total score.

SGRQ is a 76-item questionnaire developed to measure health in chronic airflow limitation. SGRQ consists of scores from three component that are used to calculate the total score: Symptoms, Activity, and Impacts on daily life. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, and Week 4, 12, 26, 40, 52).

The Total score range is from 0 to 100 (0=Best, 100=Worst); lower scores correspond to better health.

SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52).
Baseline (Week 0), Week 4, 12, 26, 40, 52.
11b_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Symptoms Score
Zeitfenster: Baseline (Week 0), Week 4, 12, 26, 40, 52.

Change from baseline in Saint George's respiratory questionnaire (SGRQ) -- Symptoms Score.

SGRQ is a questionnaire developed to measure health in chronic airflow limitation.

SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52).

Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Symptoms.

The Symptoms score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.
Baseline (Week 0), Week 4, 12, 26, 40, 52.
11c_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Impacts Score
Zeitfenster: Baseline (Week 0), Week 4, 12, 26, 40, 52.

Saint George's respiratory questionnaire (SGRQ) -- Impacts Score.

SGRQ is a questionnaire developed to measure health in chronic airflow limitation.

SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52).

Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Impacts.

The Impact score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.
Baseline (Week 0), Week 4, 12, 26, 40, 52.
11d_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Activity Score
Zeitfenster: Baseline (Week 0), Week 4, 12, 26, 40, 52.

Saint George's respiratory questionnaire (SGRQ) -- Activity score.

SGRQ is a questionnaire developed to measure health in chronic airflow limitation.

SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52).

Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Activity.

The Activity score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.
Baseline (Week 0), Week 4, 12, 26, 40, 52.
12_Number of Participants With Saint George's Respiratory Questionnaire (SGRQ) Response (Change From Baseline in Total Score ≤-4) -- at Week 26 and Week 52
Zeitfenster: Baseline (Week 0), Week 26, Week 52.

Number of participants with Saint George's Respiratory Questionnaire (SGRQ) response, defined as a change from baseline in SGRQ total score ≤ -4, at Week 26 and Week 52.

If the change from baseline was > -4, the patient was assessed as a non-responder in terms of SGRQ.

Patients with missing change from baseline at the pre-specified tested time points were also classified as non-responders.

Results shown represent the number of responder participants in terms of SGRQ, for the comparison of CHF 5993 pMDI versus CHF 1535 pMDI.
Baseline (Week 0), Week 26, Week 52.
13a_Change From Baseline for Percentage of Days Without Intake of Rescue Medication -- Over Entire Treatment Period (52 Weeks of Treatment)
Zeitfenster: Baseline (Week 0) to Week 4, 12, 26, 40, 52.

Days WITHOUT intake of rescue medication.

Change from baseline to each inter-visit period and for the entire treatment period (Week 1-52) in the percentage of days without intake of rescue medication.
Baseline (Week 0) to Week 4, 12, 26, 40, 52.
13b_Change From Baseline for the Average Use of Rescue Medication -- Over Entire Treatment Period (52 Weeks of Treatment)
Zeitfenster: Baseline (Week 0) to Week 4, 12, 26, 40, 52.

Average use of rescue medication, over the entire treatment period (52 Weeks of treatment).

Change from baseline to each inter-visit period and for the entire treatment period (Week 1-52) in the average use of rescue medication (number of puffs/day).
Baseline (Week 0) to Week 4, 12, 26, 40, 52.
14_Rate of Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Rate -- Over Entire Treatment Period (52 Weeks of Treatment)
Zeitfenster: Baseline (Week 0) to Week 52 (entire treatment period).

Rate of moderate AND severe COPD exacerbations over the entire treatment period of treatment (52 weeks).

COPD=Chronic obstructive pulmonary disease
Baseline (Week 0) to Week 52 (entire treatment period).
15_First Occurrence of All Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Zeitfenster: Baseline (Week 0), Week 52.

First occurrence of at least 1 moderate OR severe COPD exacerbation.

First occurrence was analysed by Cox regression as time to first exacerbation and reported as hazard ratio.

COPD=Chronic obstructive pulmonary disease
Baseline (Week 0), Week 52.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Chiesi Farmaceutici S.p.A.

Ermittler

  • Hauptermittler: Dave SINGH, MD, University Hospital of South Manchester, MANCHESTER M23 9 QZ, UK

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Nützliche Links

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

21. März 2014

Primärer Abschluss (Tatsächlich)

14. Januar 2016

Studienabschluss (Tatsächlich)

14. Januar 2016

Studienanmeldedaten

Zuerst eingereicht

5. August 2013

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

5. August 2013

Zuerst gepostet (Geschätzt)

6. August 2013

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

7. Mai 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • CCD-1207-PR-0091

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Beclometasone/Formoterol/Glycopyrrolate

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Bangladesh

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren